Trials / Completed
CompletedNCT02480686
Neutrino Regimen for Treatment-experienced HCV GT1 Patients
Efficacy and Safety of Neutrino Therapy for Chronic HCV Genotype 1b Treatment-experienced Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Humanity and Health Research Centre · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of NEUTRINO regimen in Chinese chronic HCV genotype 1b treatment-experienced patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOF+PEG+RBV | Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg). |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2015-06-24
- Last updated
- 2016-08-22
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02480686. Inclusion in this directory is not an endorsement.